Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Apr;39(4):456–459. doi: 10.1111/j.1365-2125.1995.tb04478.x

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.

C L Szumlanski 1, R M Weinshilboum 1
PMCID: PMC1365137  PMID: 7640156

Abstract

Thiopurine drugs are used in the treatment of inflammatory bowel disease--as are sulphasalazine and its metabolite 5-aminosalicylic acid (ASA). S-Methylation catalyzed by thiopurine methyltransferase (TPMT) is a major pathway in the metabolism of thiopurines. The hypothesis was tested that TPMT might be inhibited by sulphasalazine or isomers of ASA. Sulphasalazine as well as 3-, 4- and 5-ASA inhibited recombinant human TPMT, with IC50 values of 78, 99, 2600 and 1240 microM, respectively. Kinetic studies demonstrated that the inhibition of TPMT by sulphasalazine and ASA isomers was non-competitive with regard to the thiopurine substrate, 6-MP, and was uncompetitive with regard to the methyl donor for the reaction, S-adenosyl-L-methionine. Our observations raise the possibility of a clinically significant drug-drug interaction in patients treated simultaneously with sulphasalazine and thiopurine drugs.

Full text

PDF
456

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CLELAND W. W. Computer programmes for processing enzyme kinetic data. Nature. 1963 May 4;198:463–465. doi: 10.1038/198463a0. [DOI] [PubMed] [Google Scholar]
  2. Das K. M., Chowdhury J. R., Zapp B., Fara J. W. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology. 1979 Aug;77(2):280–284. [PubMed] [Google Scholar]
  3. Das K. M., Eastwood M. A., McManus J. P., Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973 Aug;14(8):631–641. doi: 10.1136/gut.14.8.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Evans W. E., Horner M., Chu Y. Q., Kalwinsky D., Roberts W. M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991 Dec;119(6):985–989. doi: 10.1016/s0022-3476(05)83063-x. [DOI] [PubMed] [Google Scholar]
  5. Ewe K., Press A. G., Singe C. C., Stufler M., Ueberschaer B., Hommel G., Meyer zum Büschenfelde K. H. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 1993 Aug;105(2):367–372. doi: 10.1016/0016-5085(93)90709-l. [DOI] [PubMed] [Google Scholar]
  6. Geier D. L., Miner P. B., Jr New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med. 1992 Aug;93(2):199–208. doi: 10.1016/0002-9343(92)90051-c. [DOI] [PubMed] [Google Scholar]
  7. Honchel R., Aksoy I. A., Szumlanski C., Wood T. C., Otterness D. M., Wieben E. D., Weinshilboum R. M. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol. 1993 Jun;43(6):878–887. [PubMed] [Google Scholar]
  8. Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
  9. Lennard L., Van Loon J. A., Weinshilboum R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989 Aug;46(2):149–154. doi: 10.1038/clpt.1989.119. [DOI] [PubMed] [Google Scholar]
  10. Peppercorn M. A., Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555–562. [PubMed] [Google Scholar]
  11. Present D. H., Korelitz B. I., Wisch N., Glass J. L., Sachar D. B., Pasternack B. S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980 May 1;302(18):981–987. doi: 10.1056/NEJM198005013021801. [DOI] [PubMed] [Google Scholar]
  12. Present D. H., Meltzer S. J., Krumholz M. P., Wolke A., Korelitz B. I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989 Oct 15;111(8):641–649. doi: 10.7326/0003-4819-111-8-641. [DOI] [PubMed] [Google Scholar]
  13. REMY C. N. Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem. 1963 Mar;238:1078–1084. [PubMed] [Google Scholar]
  14. Schütz E., Gummert J., Mohr F., Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993 Feb 13;341(8842):436–436. doi: 10.1016/0140-6736(93)93028-y. [DOI] [PubMed] [Google Scholar]
  15. Stark M. E., Tremaine W. J. Maintenance of symptomatic remission in patients with Crohn's disease. Mayo Clin Proc. 1993 Dec;68(12):1183–1190. doi: 10.1016/s0025-6196(12)60070-6. [DOI] [PubMed] [Google Scholar]
  16. Szumlanski C. L., Honchel R., Scott M. C., Weinshilboum R. M. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992 Aug;2(4):148–159. [PubMed] [Google Scholar]
  17. WILKINSON G. N. Statistical estimations in enzyme kinetics. Biochem J. 1961 Aug;80:324–332. doi: 10.1042/bj0800324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Weinshilboum R. M., Raymond F. A., Pazmiño P. A. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978 May 2;85(3):323–333. doi: 10.1016/0009-8981(78)90311-x. [DOI] [PubMed] [Google Scholar]
  19. Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–662. [PMC free article] [PubMed] [Google Scholar]
  20. Weinshilboum R. Methyltransferase pharmacogenetics. Pharmacol Ther. 1989;43(1):77–90. doi: 10.1016/0163-7258(89)90048-x. [DOI] [PubMed] [Google Scholar]
  21. Woodson L. C., Ames M. M., Selassie C. D., Hansch C., Weinshilboum R. M. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol. 1983 Nov;24(3):471–478. [PubMed] [Google Scholar]
  22. Woodson L. C., Dunnette J. H., Weinshilboum R. M. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther. 1982 Jul;222(1):174–181. [PubMed] [Google Scholar]
  23. Woodson L. C., Weinshilboum R. M. Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol. 1983 Mar 1;32(5):819–826. doi: 10.1016/0006-2952(83)90582-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES